A Multicenter, Open Label Long-Term Safety Study of BHV3000 in the Acute Treatment of Migraine
Phase of Trial: Phase II/III
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Adverse reactions; Registrational
- Sponsors Biohaven Pharmaceutical; Biohaven Pharmaceutical Holding Company
- 22 Jan 2019 Status changed from active, no longer recruiting to recruiting.
- 10 Dec 2018 Results (database cutoff of November 21, 2018) presented in the Biohaven Pharmaceutical media release.
- 31 Oct 2018 Planned End Date changed from 1 Oct 2019 to 1 Jul 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History